<p>一位非常看涨的分析师的举动是导致 <strong>Summit Therapeutics</strong>（SMMT -3.62%）在周中股价健康上涨的消息。根据标准普尔全球市场情报公司汇编的数据，截至周五市场开盘前，该股的上涨幅度基本保持不变，此时其股价在本周已上涨近 8%。</p>
<h2>下一个癌症重磅药物？</h2>
<p>这一消息的背后是 Evercore ISI 的分析师 Cory Kasimov，他在周三开始覆盖 Summit 的股票。他坚定地站在公司的看涨阵营，给予其 “跑赢大盘”（即：买入）评级，目标价为每股 30 美元。这意味着相较于最近的收盘股价，潜在上涨幅度超过 56%。</p>
<p>这也是一种相当大胆的方式来启动对 Summit 的覆盖，因为这家生物技术公司的股票在过去一年中已经大幅上涨。投资者对公司的主导管线药物——癌症治疗药物 ivonescimab 特别感到兴奋，尤其是考虑到它在与 <strong>默克</strong> 的重磅药物 Keytruda 的临床试验中表现良好。</p>
<p>毫不奇怪，Kasimov 对 Summit 看涨的基础是 ivonescimab，报告称他认为该药物的疗效可能比许多人意识到的更强，并且看起来将为其开发者带来丰厚的财务回报。</p>
<h2>比许多选择更好的投资</h2>
<p>癌症是生物技术市场中持久受欢迎的治疗领域，因此任何拥有有前景的肿瘤药物的开发者都会引起关注和投资。尽管如此，考虑到最近在实验室中的表现，Summit 的前景尤其令人期待，因此即使在当前高昂的价格下，它也显得是一个值得投资的选择。</p>

Summit治疗

<p>Summit 治疗的股票本周上涨了近 8%，这得益于 Evercore ISI 分析师 Cory Kasimov 的乐观评级，他给予了 “跑赢大盘” 的评级，并设定了 30 美元的目标价，暗示超过 56% 的上涨潜力。投资者对该公司领先的癌症治疗药物 ivonescimab 持乐观态度，该药物在临床试验中表现出色，相较于默克的 Keytruda 更具竞争力。Kasimov 认为 ivonescimab 的效果可能超出预期，使得 Summit 在生物科技领域的肿瘤市场中成为一个引人注目的投资选择</p>

<p>A very bullish analyst move was the news generally responsible for <strong>Summit Therapeutics</strong>' (SMMT -3.62%) healthy mid-week stock price pop. That upward lift was largely holding as of Friday before market open, as according to data compiled by S&amp;P Global Market Intelligence Summit's share price had risen by almost 8% week to date at that point.</p>
<div class="lb-trans"><p>一位非常看涨的分析师的举动是导致 <strong>Summit Therapeutics</strong>（SMMT -3.62%）在周中股价健康上涨的消息。根据标准普尔全球市场情报公司汇编的数据，截至周五市场开盘前，该股的上涨幅度基本保持不变，此时其股价在本周已上涨近 8%。</p>
</div><h2>The next cancer blockbuster drug?</h2>
<div class="lb-trans"><h2>下一个癌症重磅药物？</h2>
</div><p>The person behind the news was Evercore ISI pundit Cory Kasimov, who on Wednesday launched coverage of Summit stock. He's quite firmly in the company's bull camp, as he initiated with an outperform (read: buy) recommendation at a price target of $30 per share. That suggests hefty potential upside of over 56% on the most recent closing stock price.</p>
<div class="lb-trans"><p>这一消息的背后是 Evercore ISI 的分析师 Cory Kasimov，他在周三开始覆盖 Summit 的股票。他坚定地站在公司的看涨阵营，给予其 “跑赢大盘”（即：买入）评级，目标价为每股 30 美元。这意味着相较于最近的收盘股价，潜在上涨幅度超过 56%。</p>
</div><p>It is also quite a bold way to launch coverage of Summit, as the biotech company's stock has already soared well higher over the past year. Investors are most excited about the company's leading pipeline drug, cancer treatment ivonescimab, particularly given that it has performed well in clinical trials against <strong>Merck</strong>'s blockbuster drug Keytruda.</p>
<div class="lb-trans"><p>这也是一种相当大胆的方式来启动对 Summit 的覆盖，因为这家生物技术公司的股票在过去一年中已经大幅上涨。投资者对公司的主导管线药物——癌症治疗药物 ivonescimab 特别感到兴奋，尤其是考虑到它在与 <strong>默克</strong> 的重磅药物 Keytruda 的临床试验中表现良好。</p>
</div><p>Not surprisingly, Kasimov's bullishness on Summit is founded on ivonescimab, according to reports. He feels the drug might even prove to be more efficacious than many realize, and looks set to be very financially rewarding for its developer.</p>
<div class="lb-trans"><p>毫不奇怪，Kasimov 对 Summit 看涨的基础是 ivonescimab，报告称他认为该药物的疗效可能比许多人意识到的更强，并且看起来将为其开发者带来丰厚的财务回报。</p>
</div><h2>A better bet than many</h2>
<div class="lb-trans"><h2>比许多选择更好的投资</h2>
</div><p>Cancer is the enduringly popular therapeutic segment for the biotech market, so any developer with a promising oncology drug will attract notice and investment. That said, Summit's looks to be especially promising in light of that recent performance in the lab, and as such it feels like a worthy investment even at its current, lofty price.</p>
<div class="lb-trans"><p>癌症是生物技术市场中持久受欢迎的治疗领域，因此任何拥有有前景的肿瘤药物的开发者都会引起关注和投资。尽管如此，考虑到最近在实验室中的表现，Summit 的前景尤其令人期待，因此即使在当前高昂的价格下，它也显得是一个值得投资的选择。</p>
</div>

为什么 Summit Therapeutics 的股票本周表现出色